CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

InterviewWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1978 Questionnaire Wiki 0.12

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D003550 Cystic Fibrosis NIH 0.33
D015212 Inflammatory Bowel Diseases NIH 0.29
D005355 Fibrosis NIH 0.26
D007239 Infection NIH 0.03

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002037 Inflammation of the large intestine HPO 0.29

There are 3 clinical trials

Clinical Trials

1 Evaluation of the Repercussions of the Coronavirus (Covid 19) Infection on Nutritional Health Status and Nutritional Care : an Observational French Cohort Study One Month After Their Discharge From Hospital

Describe the main clinical features impacting the food intake, and therefore the nutritional status of a population infected by a coronavirus.

NCT04365816 COVID-1 COVID-19 Other: Interview
MeSH:Infection

Primary Outcomes

Description: Self assessment on the SEFI (Self-Evaluation of Food Intake) scale at one month after hospital discharge: 0 corresponds to the worsen score (no ingesta) and 10 corresponds to the best (same ingesta than before the disease)

Measure: Evaluation of food intake at 1 month after discharge from hospital for COVID

Time: one month after hospital discharge

Secondary Outcomes

Description: Self-reported weight in kilograms, or in the absence of self-reported variations before the disease, during hospitalisation, at hospital discharge, one month after hospital discharge

Measure: Weight variation during the infection

Time: one month after hospital discharge

Description: Effect of these factors (anorexia, dysgeusia, Ear Nose and Throat pain, swallowing disorders, intestinal transit disorders...) on SEFI and weight

Measure: Clinical signs limiting food intake

Time: one month after hospital discharge

Description: Effect of these factors (supply difficulties, disease-related food disgust, limiting food habits or prior diet, hydration difficulties, need for help) on SEFI and weight

Measure: Factors limiting food intake

Time: one month after hospital discharge

Description: Effect of nutritional strategy and interventions that were implemented (nutritional advice, adapted meals, oral nutritional supplementation, enteral and parenteral nutrition during hospitalisation and one month after hospital discharge) on SEFI and weight

Measure: Implemented nutritional strategy

Time: one month after hospital discharge

Description: Effect of pre-existing chronic disorders (pulmonary, chronic inflammatory bowel disease, cardio-vascular disease, diabetes, obesity, cognitive disorders, immunodepression, cancer, inflammatory joint disorder) on SEFI and weight

Measure: Pre-existing chronic disorders

Time: one month after hospital discharge

Description: Quantifying unscheduled consultations or hospitalisations in the month following discharge from hospital

Measure: Covid-19 repercussions

Time: one month after hospital discharge

2 The Effect of Patient's Perceptions for COVID-19 on the Inflammatory Bowel Disease-related Healthcare Utilization in the Hyperepidemic Area

The rapid spread of COVID-19 is expected to have a significant impact on medicine as well as all sectors worldwide. In particular, inflammatory bowel disease (IBD) is a chronic immune disease in which remission and activation are repeated and must be treated consistently throughout life. In addition, patients with IBD may be vulnerable to various infectious diseases due to the immuno-compromised state due to the use of immuno-suppressants or biological agents. During a pandemic, patients with IBD may postpone hospital visits due to concerns about infection with COVID-19, and if they cannot continue drug treatment, there is a concern about the flare up IBD disease activity. Therefore, in this study, we would like to investigate the current status of hospital utilization of IBD patients in Daegu, the epidemic area of COVID-19, and to investigate the effect of patient perception of COVID-19 on hospital ultilization.

NCT04387279 COVID-19 Perception, Self Facilities and Services Utilization Other: Interview
MeSH:Inflammatory Bowel Diseases
HPO:Inflammation of the large intestine

Primary Outcomes

Description: Correlation between patient's perception of COVID-19 and medical use patterns during the pandemic period

Measure: Patient's perception of COVID-19 and medical use patterns

Time: 1day

Secondary Outcomes

Description: Exacerbation of symptoms in patients with IBD during the pandemic period

Measure: Exacerbation of symptoms

Time: 1day

3 Impacts of the Covid-19 Epidemic and Associated Lockdown Measures on the Management, Health and Behaviors of Cystic Fibrosis Patients During the 2020 Epidemic

Impacts of the Covid-19 epidemic and associated lockdown measures on the management, health and behaviors of cystic fibrosis patients during the 2020 epidemic

NCT04463628 Cystic Fibrosis in Children Cystic Fibrosis Behavioral: Questionnaire Behavioral: Interview
MeSH:Cystic Fibrosis Fibrosis

Primary Outcomes

Description: Number of consultations cancelled or postponed by the health professional or patient of consultations (medical and paramedical),

Measure: Cancellation or postponement of consultations by the health professional or patient,

Time: Up to 6 months

Description: Number of consultations cancelled by the teleconsultation/replacement patient,

Measure: Patient cancellation of teleconsultations/telecare replacement,

Time: Up to 6 months

Description: Number of consultations cancelled or postponed by the health care institution or by the patient of hospitalizations (acute or scheduled)

Measure: Cancellation or postponement by the health care institution or by the patient of hospitalizations (scheduled or unscheduled),

Time: Up to 6 months

Description: Number of patients affected by the change in the modality of administration of antibiotic cures (intravenous instead of intravenous administration).

Measure: Change in the modalities of administration of antibiotics cures (oral instead of intravenous administration).

Time: Up to 6 months

Secondary Outcomes

Description: Cancellation or postponement by the patient of consultations (medical or paramedical) Patient cancellation of teleconsultations/telecare proposed by the health professional Cancellation or postponement by the patient of hospitalizations (acute or scheduled)

Measure: The reduction of each of the elements of care provision and health care utilization:

Time: Up to 6 months

Description: Intravenous instead of intravenous administration

Measure: The change of modality of administration of antibiotic cures

Time: Up to 6 months

Description: Questionnaire about taking or not taking treatment during confinement

Measure: Compliance

Time: Up to 6 months

Description: Scale 0-21

Measure: Anxiety and stress (at risk of being affected by COVID-19 or at risk of being treated less well)

Time: Up to 6 months

Description: A questionnaire on the presence or absence of toxic consumption

Measure: Presence or absence of toxic consumption (drug, alcohol) during the lockdown

Time: Up to 6 months

Description: Experience and social representations of confinement by cystic fibrosis patients (evaluated by qualitative methods)

Measure: Evaluation of the knowledge, experience and social representations of the risk of Covid-19

Time: Up to 6 months

Description: Role of social inequalities in the consequences of containment assessed by qualitative methods

Measure: Assessing the role of social inequalities in the consequences of lockdown

Time: Up to 6 months

Description: Prevalence of suspected and/or confirmed Covid-19 infections in patients with cystic fibrosis

Measure: Suspected and/or confirmed Covid-19 in patients with cystic fibrosis.

Time: Up to 6 months

Related HPO nodes (Using clinical trials)

HP:0002037: Inflammation of the large intestine
Genes 57
RFXANK MAP3K7 NLRC4 IL10RA WIPF1 BACH2 STAT1 FOXP3 RTEL1 FASLG ABCB1 WAS NOD2 TGFB1 IL10RB CASP10 XIAP FAS MASP2 RIPK1 IRGM ZAP70 COG6 RASGRP1 FERMT1 CIITA INAVA OPLAH GPR35 MST1 HLA-DRB1 CARMIL2 WAS TTC37 SKIV2L SLC9A3 PLCG2 ARPC1B SKIV2L LRBA RFX5 HLA-B TNFAIP3 FAS IL6 ZAP70 RFXAP NCF4 F13A1 PRKCD TCF4 RET POLA1 F13B IL21 HPS1 GPIHBP1
Protein Mutations 1
R139C
SNP 9
rs1217414 rs12760457 rs1310182 rs2097432 rs2476601 rs2488457 rs33996649 rs3789604 rs9557195